ES2569477T3 - Combinación de un inhibidor de HDAC y un antimetabolito - Google Patents

Combinación de un inhibidor de HDAC y un antimetabolito Download PDF

Info

Publication number
ES2569477T3
ES2569477T3 ES07862420.2T ES07862420T ES2569477T3 ES 2569477 T3 ES2569477 T3 ES 2569477T3 ES 07862420 T ES07862420 T ES 07862420T ES 2569477 T3 ES2569477 T3 ES 2569477T3
Authority
ES
Spain
Prior art keywords
combination
antimetabolite
hdac inhibitor
methyl
hdai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07862420.2T
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2569477(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2569477T3 publication Critical patent/ES2569477T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una combinación de (a) un inhibidor de desacetilasa de histona (HDAI); y (b) un anti-metabolito; en donde (a) es N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)-etil]-amino]metil]fenil]-2E-2-propenamida, o una sal farmacéuticamente aceptable de la misma, y (b) es 5-azacitidina para utilizarse en el tratamiento de una enfermedad proliferativa que es síndrome mielodisplásico (MDS) o leucemia mieloblástica aguda (AML).

Description

imagen1
-
imagen2
imagen3
imagen4
imagen5
-
imagen6
--

Claims (1)

  1. imagen1
    -
ES07862420.2T 2006-12-04 2007-11-30 Combinación de un inhibidor de HDAC y un antimetabolito Active ES2569477T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86838806P 2006-12-04 2006-12-04
US868388P 2006-12-04
PCT/US2007/024712 WO2008070011A2 (en) 2006-12-04 2007-11-30 Combination of an hdac inhibitor and an antimetabolite

Publications (1)

Publication Number Publication Date
ES2569477T3 true ES2569477T3 (es) 2016-05-11

Family

ID=39272127

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07862420.2T Active ES2569477T3 (es) 2006-12-04 2007-11-30 Combinación de un inhibidor de HDAC y un antimetabolito

Country Status (26)

Country Link
US (1) US8093220B2 (es)
EP (1) EP2099451B1 (es)
JP (3) JP5784274B2 (es)
KR (1) KR101475538B1 (es)
CN (1) CN101553223A (es)
AR (1) AR064072A1 (es)
AU (1) AU2007328281B2 (es)
BR (1) BRPI0719746A2 (es)
CA (1) CA2670741C (es)
CL (1) CL2007003467A1 (es)
EC (1) ECSP099483A (es)
ES (1) ES2569477T3 (es)
GT (1) GT200900148A (es)
HK (1) HK1132462A1 (es)
IL (1) IL198638A (es)
MA (1) MA30982B1 (es)
MX (1) MX2009005946A (es)
MY (1) MY148893A (es)
NO (1) NO20092473L (es)
PE (1) PE20081303A1 (es)
PL (1) PL2099451T3 (es)
RU (1) RU2469717C2 (es)
TN (1) TN2009000213A1 (es)
TW (1) TW200831075A (es)
WO (1) WO2008070011A2 (es)
ZA (1) ZA200903041B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2519474T3 (es) * 2008-03-26 2014-11-07 Novartis Ag Inhibidores de las desacetilasas B basados en hidroxamato
WO2010009285A1 (en) * 2008-07-18 2010-01-21 Novartis Ag Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome
BRPI0915927A2 (pt) * 2008-07-18 2016-06-07 Novartis Ag uso de inibiodores de hdac para o tratamento da doença de hodgkin
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
RU2016103126A (ru) * 2010-06-07 2018-11-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы комбинированной терапии для лечения пролиферативных заболеваний
KR20130101519A (ko) * 2010-09-01 2013-09-13 노파르티스 아게 Ｈｄａｃ 억제제와 혈소판감소증 약물의 조합물
WO2014164708A1 (en) * 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
CN105960239A (zh) 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法
KR20170048601A (ko) 2014-09-17 2017-05-08 셀젠 콴티셀 리서치, 인크. 히스톤 탈메틸효소 억제제
SG11201707418WA (en) 2015-03-13 2017-10-30 Forma Therapeutics Inc Alpha-cinnamide compounds and compositions as hdac8 inhibitors
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP2006528952A (ja) * 2003-05-21 2006-12-28 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤と化学療法剤の組み合わせ

Also Published As

Publication number Publication date
MY148893A (en) 2013-06-14
JP2016006070A (ja) 2016-01-14
HK1132462A1 (zh) 2010-02-26
US20100069318A1 (en) 2010-03-18
PL2099451T3 (pl) 2016-07-29
JP5784274B2 (ja) 2015-09-24
US8093220B2 (en) 2012-01-10
KR101475538B1 (ko) 2014-12-22
ECSP099483A (es) 2009-08-28
RU2009125439A (ru) 2011-01-20
IL198638A (en) 2015-06-30
TW200831075A (en) 2008-08-01
GT200900148A (es) 2011-08-02
KR20090087115A (ko) 2009-08-14
WO2008070011A2 (en) 2008-06-12
CL2007003467A1 (es) 2008-07-11
EP2099451B1 (en) 2016-02-10
JP2010511702A (ja) 2010-04-15
PE20081303A1 (es) 2008-10-28
AR064072A1 (es) 2009-03-11
JP2014097992A (ja) 2014-05-29
MA30982B1 (fr) 2009-12-01
ZA200903041B (en) 2010-03-31
CN101553223A (zh) 2009-10-07
WO2008070011A3 (en) 2008-07-24
RU2469717C2 (ru) 2012-12-20
IL198638A0 (en) 2010-02-17
BRPI0719746A2 (pt) 2013-12-10
CA2670741C (en) 2016-04-12
EP2099451A2 (en) 2009-09-16
TN2009000213A1 (en) 2010-10-18
CA2670741A1 (en) 2008-06-12
AU2007328281A1 (en) 2008-06-12
NO20092473L (no) 2009-09-01
MX2009005946A (es) 2009-06-17
AU2007328281B2 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
ES2569477T3 (es) Combinación de un inhibidor de HDAC y un antimetabolito
ES2545076T3 (es) Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma
ES2524556T3 (es) Composiciones farmacéuticas
ES2545205T3 (es) Combinación de azelastina y ciclesonida
ES2515168T3 (es) Detección y tratamiento de la esquizofrenia
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2522567T3 (es) Composición farmacéutica que comprende amlodipino y losartán
ES2629749T3 (es) Inmunidad tumoral
AR061298A1 (es) Sales de n-hidroxi -3- [4- [ [ [2- (2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2- propenamida.composciones farmaceuticas.
ECSP099086A (es) Comprimido masticable que contiene fenilefrina
CL2007003108A1 (es) Compuestos derivados de n-hidroxiamida sustituida con heterociclos, inhibidores de histona desacetilasa; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad del grupo que consiste en enfermedad de huntington,
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
NZ599464A (en) Combination therapies using hdac inhibitors
ECSP088957A (es) Composición farmacéutica estable que contiene docetaxel y método para su fabricación
RU2018140051A (ru) Производные нестероидных противовоспалительных средств
CL2011000100A1 (es) Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin.
RS52638B (en) HISTONAL DEACETYLASE INHIBITORS WITH COMPOUND ACTIVITY AGAINST CLASS-I AND CLASS-IIB HISTONAL DEACETYLASES IN COMBINATION WITH PROTEAS INHIBITORS
RU2013114246A (ru) Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении
ES2523428T3 (es) Parche para administración transdérmica
GEP20074253B (en) Agent for treatment of joint disease
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
JP2010540461A5 (es)
AR042037A1 (es) Profarmaco de celecoxib
JP2006516279A5 (es)
EA200601410A1 (ru) Новая комбинация агомелатина и ингибитора обратного поглощения норадреналина и фармацевтические композиции, которые её содержат